Clinical Trial

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

Study acronym: SARC-ONCO
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-15.
Status change: Not Yet Recruiting → Recruiting 2024-07-17
Trial Details
NCT Number NCT06274268
Lead Sponsor Centre Hospitalier Metropole Savoie
Collaborators: Université Savoie Mont Blanc
Conditions Sarcopenia, Oncology, Physical Inactivity, Toxicity Due to Chemotherapy
Enrollment 700 participants
Start Date 2024-06-24
Primary Completion 2027-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-18